Lawsuit filed for Investors in shares of TransMedics Group, Inc. (NASDAQ: TMDX) over alleged Securities Laws Violations

An investor, who purchased shares of TransMedics Group, Inc. (NASDAQ: TMDX), filed a lawsuit over alleged violations of Federal Securities Laws by TransMedics Group, Inc.

Investors who purchased shares of TransMedics Group, Inc. (NASDAQ: TMDX) have certain options and for certain investors are short and strict deadlines running. Deadline: April 15, 2025. NASDAQ: TMDX investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.

Andover, MA baqsed TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. On February 21, 2024, U.S. Representative and member of the House Committee on Oversight and Accountability Paul Gosar issued a letter accusing the Company of misconduct including overcharging for OCS and misappropriating corporate resources.

On October 28, 2024, TransMedics Group, Inc. reported that its revenue growth for 3Q 24 was roughly half that reported in 2Q 24. Still, TransMedics assured investors that the disappointing growth was not caused by a change in competitive dynamics or market share loss.

On December 2, 2024, TransMedics Group, Inc. announced the resignation of its CFO from that role and narrowed its financial outlook for 2024. Then, on January 10, 2025, Scorpion Capital issued a research report explaining that TransMedics's growth was fueled by an anti-competitive scheme that included kickbacks to medical providers to use the company's products and that TransMedics further boosted growth by operating an organ trafficking scheme, engaged in widespread billing fraud, and promoted off-label use.

Then, on January 10, 2025, Scorpion Capital issued a research report explaining that TransMedics's growth was fueled by an anti-competitive scheme that included kickbacks to medical providers to use the company's products and that TransMedics further boosted growth by operating an organ trafficking scheme, engaged in widespread billing fraud, and promoted off-label use.

Shares of TransMedics Group, Inc. (NASDAQ: TMDX) declined from $177.37 per share on august 23, 2024 to as low a $55.00 per share on January 21, 2025.

The plaintiff claims that between February 28, 2023 and January 10, 2025, the defendants made false and/or misleading statements and/or failed to disclose that TransMedics used kickbacks, fraudulent overbilling, and coercive tactics to generate business and revenue, that TransMedics engaged in unsafe practices and hid safety issues and generally lacked safety oversight, that the foregoing subjected TransMedics to heightened risk of scrutiny and regulatory risk, and that as a result, defendants' statements about TransMedics' business, operations, and prospects, were materially false and misleading and/or lacked a reasonable basis at all relevant times

Those who purchased shares of TransMedics Group, Inc. (NASDAQ: TMDX) have certain options and should contact the Shareholders Foundation.

Contact:
Michael Daniels
Shareholders Foundation, Inc.
3111 Camino Del Rio North
Suite 423
San Diego, CA 92108
Tel: +1-(858)-779-1554
E-Mail: mail@shareholdersfoundation.com

About Shareholders Foundation, Inc.
The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claim filing service, and an investor advocacy group, which does research related to shareholder issues and informs investors of securities lawsuits, settlements, judgments, and other legal related news to the stock/financial market. Shareholders Foundation, Inc. is in contact with a large number of shareholders and offers help, support, and assistance for every shareholder. The Shareholders Foundation, Inc. is not a law firm. Referenced cases, investigations, and/or settlements are not filed/initiated/reached and/or are not related to Shareholders Foundation. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.

This release was published on openPR.